Search clinical trials for: Liver metastases from colorectal cancer (mCRC)

Total 109420 results

Second Affiliated Hospital, School of Medicine,...
Shanghai Junshi Bioscience Co., Ltd.; Qilu Pharmaceutical Co., Ltd.

Unknown

QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer (BEVTOR)

MSS | pMMR | Refractory Metastatic Colorectal Cancer

China
GERCOR - Multidisciplinary Oncology Cooperative...
Bristol-Myers Squibb

Recruiting

Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE)

Colorectal Cancer Metastatic | MSI-H Colorectal Cancer

France
Ospedale Policlinico San Martino
CRO "Centro Clinical Trials" IRCCS Ospedale Policlinico San Martino; Laboratory...

Withdrawn

Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy (Bohème)

Metastatic Colorectal Cancer
Centre Georges Francois Leclerc
AstraZeneca

Completed

Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC (MEDITREME)

Colorectal Cancer Metastatic

France
Zhejiang University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients (ALTER-C-002)

Digestive System Diseases | Gastrointestinal Diseases | Neoplasms | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Colonic Diseases | Intestinal Diseases | Colorectal Neoplasms | Intestinal Neoplasms | Rectal Diseases | Colorectal Cancer | RAS and BRAF Wild-type

China
PharmaEngine

Completed

Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy

Metastatic Colorectal Cancer

Taiwan
Asan Medical Center

Withdrawn

Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines

Metastatic Colorectal Cancer

Korea, Republic of
The First Affiliated Hospital of Xiamen University

Recruiting

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

Colorectal Neoplasms

China
Sinocelltech Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Gritstone bio, Inc.

Active, not recruiting

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

United States
SCRI Development Innovations, LLC
Pfizer

Completed

A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

Colorectal Cancer

United States
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Terminated

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Colorectal Neoplasm

Korea, Republic of
Genentech, Inc.

Completed

Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) (MAVERICC)

Colorectal Cancer

Canada, United States, Estonia, Portugal, Switzerland, Ireland, Norway
Wuhan Union Hospital, China

Recruiting

Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC

Colorectal Neoplasms Malignant

China
Lutris Pharma Ltd.

Recruiting

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

EGFRI Induced Acneiform Lesions

United States, Israel
GB006, Inc., a wholly owned subsidiary of Gossamer...
Merck Sharp & Dohme LLC

Terminated

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Renal Cell Carcinoma | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Castration-resistant Prostate Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Adenocarcinoma | Esophageal... and other conditions

United States, United Kingdom
Letolab

Not yet recruiting

Phase II Clinical Study of LTC004 in Patients With mCRC

Locally Advanced or Metastatic CRC
Zhen-Yu Ding

Completed

A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC） (DOFEMCRC)

Colorectal Cancer

China
Shanghai Zhongshan Hospital

Recruiting

Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC

Colorectal Neoplasms Malignant

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Astex Therapeutics, Ltd; Susan Cohan Colon Cancer Foundation

Completed

SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

United States
Bayer

Completed

Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy (RECORA)

Colorectal Neoplasm

Germany
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

Solid Tumor

China
US Oncology Research
Quintiles, Inc.

Completed

Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)

Colorectal Neoplasms | Advanced Metastatic Colorectal Cancer

United States
Amgen

Completed

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Colon Cancer | Gastrointestinal Cancer
Novartis Pharmaceuticals

Active, not recruiting

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3)

Metastatic Colorectal Cancer

Canada, Taiwan, Belgium, Germany, Spain, Italy, Czechia, Switzerland, Australia, United States, Japan, Singapore, United Kingdom, France, Israel, Hong Kong, Korea, Republic of
Gilead Sciences

Active, not recruiting

Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC)

Metastatic Colorectal Cancer

United States, Spain, Australia, Hong Kong, France, Belgium, Canada, Puerto Rico, Germany, Italy
ARCA Biopharma, Inc.

Suspended

Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer

Colon Cancer

United States
Zhejiang Cancer Hospital

Not yet recruiting

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Metastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRC

China
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

CRC

China
Gruppo Oncologico del Nord-Ovest

Unknown

Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (CRICKET)

Metastatic Colorectal Cancer

Italy
Chandrikha Chandrasekharan
AstraZeneca; Biocompatibles UK Ltd

Suspended

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (iRE-C)

Metastatic Colorectal Cancer | Colorectal Neoplasms | Rectal Cancer | Colon Cancer | Colorectal Cancer Metastatic | Liver Metastases | Colo-rectal Cancer | Colorectal Carcinoma | Colorectal Adenocarcinoma | Liver Metastasis Colon Cancer

United States
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

Metastatic Colorectal Cancer

China
Amgen

Completed

ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line (SILQ)

Metastatic Colorectal Cancer

Italy
Spanish Cooperative Group for the Treatment of...
Bayer

Terminated

Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab (PREVIUM)

Colorectal Neoplasms | Metastatic Disease

Spain
Shanghai Zhongshan Hospital

Active, not recruiting

Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC

Colorectal Neoplasms

China
Fudan University

Not yet recruiting

Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study

Metastatic Colorectal Cancer
Scandion Oncology A/S
TFS Trial Form Support

Recruiting

A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI

Metastatic Colorectal Cancer

Denmark, Spain, Germany
Amgen
ZeinCRO Hellas SA

Completed

Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR (VISION)

Metastatic Colorectal Cancer

Greece
Diwakar Davar
Aculeus Therapeutics

Active, not recruiting

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

NSCLC | Metastatic Colorectal Carcinoma | Refractory Melanoma

United States
Gruppo Oncologico del Nord-Ovest

Unknown

Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC (TRIBE2)

Metastatic Colorectal Cancer

Italy
Genentech, Inc.

Completed

Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)

Colorectal Cancer

Australia, Belgium, Spain, United States, New Zealand, United Kingdom, Italy, Romania, France, Germany
Merck KGaA, Darmstadt, Germany
Merck Quimica Argentina S.A.I.C

Completed

Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients

Colorectal Neoplasms

Argentina
National Cancer Institute (NCI)

Recruiting

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

United States
Taiwan Sunpan Biotechnology Development Co., Ltd.
Virginia Contract Research Organization Co., Ltd.

Completed

To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC. (TSB-9-W1)

Metastatic Colorectal Cancer

Taiwan
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

Cetuximab-induced Papulopustular (Acneiform) Rash Who Have | Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma

United States
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Metastatic Colorectal Cancer | Squamous Cell Carcinoma of Head and Neck (SCCHN)

France, Belgium, Spain, Germany, Italy, Canada, United States
China Medical University, China

Recruiting

Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.

Metastatic Colorectal Adenocarcinoma | MSS | pMMR

China
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

China
Merck Sharp & Dohme LLC
Array BioPharma

Completed

Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)

Metastatic Colorectal Cancer

United States, Canada
Martin-Luther-Universität Halle-Wittenberg
GALMED GmbH

Completed

TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC) (AIO-KRK-0111)

Colorectal Cancer

Germany

3

Subscribe